Authors: T.Ya. Chursina (1), K.O. Mikhaliev (2)
(1) Bukovinian State Medical University, Chernivtsi, Ukraine
(2) State Scientific Institution “Scientific and Practical Center of Preventive and Clinical Medicine” of the Agency of State Affairs,
Kyiv, Ukraine
Resume
Community-acquired pneumonia is one of the most common infectious diseases of the 21st century and remains an important medical and social problem due to the relatively high rates of disability and mortality, as well as significant economic losses. Concomitant chronic diseases and conditions, the number of which increases with age, determine the severity and unfavorable prognosis of pneumonia. The combination of pathologies, the pathogenesis of which includes a hypoxic component, in one patient determines the crucial importance and need to understand the mechanisms of hypoxia (including at the cellular level), as well as the social significance of the problem of protecting the body from oxygen deficiency and concomitant energy deficiency, in particular with the help of antihypoxants with antioxidant and membrane-stabilizing action. Numerous experimental and clinical studies have shown data on the pleiotropic effects of succinate and succinate-containing antihypoxants in patients with diseases and conditions that are accompanied by hypoxic disorders. A sufficient evidence base of clinical studies has been created, in which the expediency of using ethylmethylhydroxypyridine succinate as a part of comprehensive therapy in patients with acute and chronic cerebrovascular disorders, anxiety disorders, stable angina, acute coronary syndrome, heart failure, arterial hypertension has been established. Early addition of the drug to the combination therapy at the prehospital stage of pneumonia treatment will help reduce the occurrence of acute complications or decompensation of concomitant chronic conditions, accelerate the regression of post-infectious asthenia, autonomic lability, cognitive deficits.
Keywords: community-acquired pneumonia; hypoxia; ethylmethylhydroxypyridine succinate
Download the article in PDF (Ukr)